Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110107 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 376
- Enrollment target
NCT03110107 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 376 participants.
The verdict
NCT03110107, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL BMS-986218
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110107
The ClinicalTrials.gov registry entry for NCT03110107 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03110107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110107 about?
NCT03110107 is a clinical study titled "First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
What is the current status of trial NCT03110107?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 376 participants. The study started on 2017-05-04. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT03110107?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986218 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03110107?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.